Clinical trials: Clarithromycin
Healthy
Clarithromycin 500 mg Tablets Under Non-Fasting Conditions
This study will compare the relative bioavailability (rate and extent of absorption) of 500 mg Clarithromycin Tablets with that of 500 mg BIAXIN® Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult subjects…
- Trial name
- NCT00836706
- Testing
- clarithromycin, BIAXIN®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Helicobacter Pylori Infection
Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection
This is an open-label, randomized controlled trial. The aim of the study is to evaluate the efficacy and safety of the Qingre Huashi Granules combined the modified dual therapy (or called high dose dual therapy) for Helicobacter…
- Trial name
- NCT05364619
- Testing
- Qingre Huashi Granules combined the modified dual therapy, Bismuth containing quadruple therapy
- Where
- 3 sites in China
- Volunteers
- 160 people
- Sponsor
- Peking University First Hospital
Depressive Disorder, Major
A Study to Evaluate the Effect of Clarithromycin on LY2216684
The study will evaluate the effect of Clarithromycin on the pharmacokinetics (PK) of LY2216684 in healthy participants. Side effects will be documented.
- Trial name
- NCT01460407
- Testing
- LY2216684, Clarithromycin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
This phase II trial studies lenalidomide, dexamethasone, and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT00445692
- Testing
- Clarithromycin, Dexamethasone, Lenalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Sepsis, Pneumonia
Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System
High mortality associated with sepsis and Multiple Organ Dysfunction Syndrome (MODS) calls for alternative, individualized therapies in selected patients that might benefit form specific interventions.
- Conditions
- Sepsis, Pneumonia, Gram-Negative Bacteria Infection, Multiple Organ Failure
- Trial name
- INCLASS (NCT03345992)
- Testing
- Clarithromycin, Water for injection
- Where
- 12 sites in Belgium, Greece
- Volunteers
- 110 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Helicobacter Pylori Infection
The Role of Probiotics in the Eradication of Helicobacter Pylori
All patients will receive quadruple eradication therapy for 10 days with Omerazole 20mg x2, Amoxicilin 1g x2, Clarithromycin 500mg x2 and Metronidazole 500mg x2. The patients will be randomised into two groups.
- Trial name
- NCT04178187
- Testing
- Caps Lactolevure
- Where
- 5 sites in Greece
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Evangelismos Hospital
the Eradication Rates of Helicobacter Pylori
Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication
The goal of this clinical trial is to compare eradication rates of Helicobacter pylori in patients aged 18-70 years with first infection.
- Trial name
- NCT06168214
- Testing
- Rabeprazloe+bismuth+amoxicillin+clarithromycin, Vonoprazan+amoxicillin+clarithromycin 14 days, Vonoprazan+amoxicillin+clarithromycin 7 days
- Where
- China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital of Digestive Diseases
Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
The purpose of the study is to evaluate the efficacy of bedaquiline (BDQ) compared with rifamycin when administered as part of a treatment regimen with clarithromycin (CAM) and ethambutol (EB) in adult participants with…
- Trial name
- NCT04630145
- Testing
- Bedaquiline, Clarithromycin, Ethambutol
- Where
- 55 sites in Japan, South Korea and 1 more
- Volunteers
- 129 people
- Sponsor
- Janssen Pharmaceutical K.K.
Parkinson Disease
Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm
The arm of this study evaluates possible GABA-A receptor target engagement effects of the FDA-approved medication, transdermal flumazenil (added 4/2020, replaced clarithromycin), in the setting of Parkinson's disease.
- Trial name
- GABA-A (NCT03440112)
- Testing
- Clarithromycin (Not used as of 4/2020), Transdermal flumazenil (Added 4/2020)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Nicolaas Bohnen, MD, PhD
Helicobacter Pylori Infection
Intraluminal Therapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is the most common chronic bacterial infection in humans. The prevalence of H. pylori is about 30~50% in the Western adult population.
- Trial name
- NCT03124420
- Testing
- Lansoprazole, Amoxicillin, Clarithromycin
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Mackay Memorial Hospital
H. Pylori Infection
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
The purpose of this study is to confirm the efficacy of triple therapy with TAK-438, Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to triple therapy with Lansoprazole, Amoxicillin and…
- Trial name
- NCT01505127
- Testing
- TAK-438, Lansoprazole, Amoxicillin
- Where
- 35 sites in Japan
- Volunteers
- 650 people
- Sponsor
- Takeda
Helicobacter Pylori Infection
Fecal Molecular Susceptibility-guided Hp Rescue Therapy
The goal of this clinical trial is to evaluate the eradication efficacy and health economic benefits of individualized regimens guided by fecal molecular susceptibility testing with 7-day and 14-day courses in the rescue…
- Trial name
- NCT07405697
- Testing
- 7-day fecal molecular susceptibility-guided therapy, 14-day fecal molecular susceptibility-guided therapy
- Where
- 4 sites in China
- Volunteers
- 290 people
- Sponsor
- Shanghai Zhongshan Hospital
Helicobacter Pylori Eradication
Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective Randomized Trial
Although Urea breath test has been commonly used to recheck the efficiency of Helicobacter pylori eradication, there has been no randomized trials comparing the accuracy of Urea breath test results at different times after…
- Trial name
- NCT05870397
- Testing
- HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hyperaldosteronism
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)
This study evaluates if : 1 ) the plasma aldosterone concentration and blood pressure change in response to roxithromycin could be useful for the screening of PA patients carrying a KCNJ5-mutated APA; 2) the change of PAC in…
- Trial name
- MAPA (NCT03414918)
- Testing
- Clarithromycin
- Where
- Italy
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- University Hospital Padova
Helicobacter Pylori Infection
Tailored Therapy for Clarithromycin-Resistant H. Pylori
Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been…
- Trial name
- NCT03431688
- Testing
- PAM, PBMT
- Where
- South Korea
- Volunteers
- 782 people
- Sponsor
- Kangdong Sacred Heart Hospital
Helicobacter Pylori Infection
Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication
Helicobacter pylori (HP), a bacterium present in many people's stomachs, is one of the major causes of ulcers and cancers. Up to 20% of patients infected with H. pylori may develop peptic ulcers.
- Trial name
- NCT01760824
- Testing
- Sequential therapy, Quadruple therapy
- Where
- Hong Kong
- Volunteers
- 391 people
- Sponsor
- The University of Hong Kong
Acute Bacterial Sinusitis (ABS)
Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis
To compare the safety/tolerability and efficacy of a 14-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 14-day course of amoxicillin-clavulanate tablets (875/125 mg BID) for the treatment of…
- Trial name
- NCT00644553
- Testing
- Clarithromycin, Amoxicillin
- Where
- 53 sites in United States, Canada and 7 more
- Volunteers
- 437 people
- Sponsor
- Abbott
Pneumonia
A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting
The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.
- Trial name
- NCT00034736
- Testing
- Levofloxacin
- Volunteers
- 691 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults
This is an open-label, fixed-sequence, phase 1 study to evaluate the effect of clarithromycin/rifampicin on the pharmacokinetics of DA-8010 in healthy adults.
- Trial name
- NCT05991401
- Testing
- DA-8010 5mg, Clarithromycin 500mg, Rifampicin 600mg
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Mycobacterium Ulcerans Infection
WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8
This is a WHO-sponsored trial. Combination therapy with streptomycin and rifampicin has been the standard antibiotic treatment for M. ulcerans infection since 2004.
- Trial name
- NCT01659437
- Testing
- Clarithromycin Extended Release, Streptomycin intramuscular injection
- Where
- 5 sites in Benin, Ghana
- Volunteers
- 310 people
- Sponsor
- University Medical Center Groningen